公开(公告)号：US11952427B2

公开(公告)日：2024-04-09

申请号：US17694890

申请日：2022-03-15

Applicant: Bristol-Myers Squibb Company ,  CytomX Therapeutics, Inc.

Inventor： Bryan C. Barnhart ,  Brigitte Devaux ,  Aaron P. Yamniuk ,  Shannon L. Okada ,  Brenda L. Stevens ,  James William West

IPC: C07K16/28 ,  C12N15/63

CPC classification number: C07K16/2878 ,  C12N15/63 ,  C07K2317/56

Abstract: Provided herein are agonistic antibodies, or antigen binding portions thereof, that bind to human CD40 and comprise improved heavy and light chain variable regions that impart improved yield and reduced aggregation. The invention also provides methods of treatment of cancer or chronic infection by administering the antibodies of the invention to a subject in need thereof.

公开(公告)号：US11352440B2

公开(公告)日：2022-06-07

申请号：US16117183

申请日：2018-08-30

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Nils Lonberg ,  Alan J. Korman ,  Bryan C. Barnhart ,  Aaron P. Yamniuk ,  Mohan Srinivasan ,  Karla A. Henning ,  Ming Lei ,  Emanuela Sega ,  Angela Goodenough ,  Maria N. Jure-Kunkel ,  Guodong Chen ,  John S. Sack ,  Richard Y. Huang ,  Martin J. Corbett ,  Joseph E. Myers, Jr. ,  Liang Schweizer ,  Sandra V. Hatcher ,  Haichun Huang ,  Pingping Zhang

IPC: A61K39/395 ,  C07K16/40 ,  C07K16/28 ,  C07K16/30 ,  G01N33/573 ,  A61K47/68 ,  A61K45/06 ,  G01N33/574 ,  A61K39/00

Abstract: The present invention provides isolated monoclonal antibodies, particularly human antibodies, that bind to human Cluster of Differentiation 73 (CD73) with high affinity, and inhibit the activity of CD73, and optionally mediate antibody dependent CD73 internalization. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for inhibiting the growth of a tumor cell expressing CD73 using the antibodies of the invention, including methods for treating various cancers.

公开(公告)号：US11306149B2

公开(公告)日：2022-04-19

申请号：US16958563

申请日：2018-12-27

Applicant: Bristol-Myers Squibb Company ,  CytomX Therapeutics, Inc.

Inventor： Bryan C. Barnhart ,  Brigitte Devaux ,  Aaron P. Yamniuk ,  Shannon L. Okada ,  Brenda L. Stevens ,  James William West

IPC: C07K16/28 ,  C12N15/63

Abstract: Provided herein are agonistic antibodies, or antigen binding portions thereof, that bind to human CD40 and comprise improved heavy and light chain variable regions that impart improved yield and reduced aggregation. The invention also provides methods of treatment of cancer or chronic infection by administering the antibodies of the invention to a subject in need thereof.

公开(公告)号：US10653791B2

公开(公告)日：2020-05-19

申请号：US15520954

申请日：2015-11-19

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Nils Lonberg ,  Alan J. Korman ,  Mark J. Selby ,  Bryan C. Barnhart ,  Aaron P. Yamniuk ,  Mohan Srinivasan ,  Karla A. Henning ,  Michelle Minhua Han ,  Ming Lei ,  Liang Schweizer ,  Sandra V. Hatcher ,  Arvind Rajpal

IPC: C07K16/00 ,  C07K16/28 ,  C07K16/30 ,  A61K47/68 ,  A61K39/395

Abstract: Provided herein are heavy chain constant regions (referred to as “modified heavy chain constant regions”), or functionally equivalent fragments thereof, that enhance biological properties of antibodies relative to the same antibodies in unmodified form. An exemplary modified heavy chain constant region includes an IgG2 hinge and three constant domains (i.e., CH1, CH2, and CH3 domains), wherein one or more of the constant region domains are of a non-IgG2 isotype (e.g., IgG1, IgG3 or IgG4). The heavy chain constant region may comprise wildtype human IgG domain sequences, or variants of these sequences. Also provided herein are methods for enhancing certain biological properties of antibodies that comprise a non-IgG2 hinge, such as internalization, agonism and antagonism, wherein the method comprises replacing the non-IgG2 hinge of the antibody with an IgG2 hinge.

公开(公告)号：US10479838B2

公开(公告)日：2019-11-19

申请号：US15195098

申请日：2016-06-28

Applicant: The Rockefeller University ,  BRISTOL-MYERS SQUIBB COMPANY

Inventor： Jeffrey V. Ravetch ,  Rony Dahan ,  Bryan C. Barnhart ,  Brigitte Devaux ,  Aaron P. Yamniuk ,  Shannon L. Okada ,  Brenda L. Stevens

IPC: A61K39/395 ,  C07K16/28 ,  A61K39/00

Abstract: Provided herein are agonistic antibodies, or antigen binding portions thereof, that bind to human CD40. Such antibodies optionally comprise Fc regions with enhanced specificity for FcγRIIb. The invention also provides methods of treatment of cancer or chronic infection by administering the antibodies of the invention to a subject in need thereof.

公开(公告)号：US10167343B2

公开(公告)日：2019-01-01

申请号：US15432180

申请日：2017-02-14

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Nils Lonberg ,  Alan J. Korman ,  Bryan C. Barnhart ,  Aaron P. Yamniuk ,  Mohan Srinivasan ,  Karla A. Henning ,  Ming Lei ,  Emanuela Sega ,  Angela Goodenough ,  Maria N. Jure-Kunkel ,  Guodong Chen ,  John S. Sack ,  Richard Y. Huang ,  Martin J. Corbett ,  Joseph E. Myers, Jr. ,  Liang Schweizer ,  Sandra V. Hatcher ,  Haichun Huang ,  Pingping Zhang

IPC: C07K16/30 ,  C07K16/40 ,  A61K39/00 ,  A61K39/395 ,  A61K45/06 ,  G01N33/573 ,  C07K16/28

Abstract: The present invention provides isolated monoclonal antibodies, particularly human antibodies, that bind to human Cluster of Differentiation 73 (CD73) with high affinity, and inhibit the activity of CD73, and optionally mediate antibody dependent CD73 internalization. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for inhibiting the growth of a tumor cell expressing CD73 using the antibodies of the invention, including methods for treating various cancers.

公开(公告)号：US09605080B2

公开(公告)日：2017-03-28

申请号：US14994828

申请日：2016-01-13

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Nils Lonberg ,  Alan J. Korman ,  Bryan C. Barnhart ,  Aaron P. Yamniuk ,  Mohan Srinivasan ,  Karla A. Henning ,  Ming Lei ,  Emanuela Sega ,  Angela Goodenough ,  Maria N. Jure-Kunkel ,  Guodong Chen ,  John S. Sack ,  Richard Huang ,  Martin J. Corbett ,  Joseph E. Myers, Jr. ,  Liang Schweizer ,  Sandra V. Hatcher ,  Haichun Huang ,  Pingping Zhang

IPC: C07K16/30 ,  C07K16/40 ,  A61K39/00 ,  A61K39/395 ,  A61K45/06 ,  G01N33/573

CPC classification number: C07K16/40 ,  A61K39/3955 ,  A61K45/06 ,  A61K2039/505 ,  C07K16/2896 ,  C07K16/30 ,  C07K16/3015 ,  C07K16/3023 ,  C07K16/303 ,  C07K16/3038 ,  C07K16/3046 ,  C07K16/3053 ,  C07K16/3061 ,  C07K16/3069 ,  C07K2317/21 ,  C07K2317/31 ,  C07K2317/34 ,  C07K2317/52 ,  C07K2317/522 ,  C07K2317/524 ,  C07K2317/526 ,  C07K2317/53 ,  C07K2317/54 ,  C07K2317/55 ,  C07K2317/565 ,  C07K2317/567 ,  C07K2317/71 ,  C07K2317/72 ,  C07K2317/76 ,  C07K2317/77 ,  C07K2317/92 ,  C07K2317/94 ,  G01N33/573 ,  G01N2333/916

Abstract: The present invention provides isolated monoclonal antibodies, particularly human antibodies, that bind to human Cluster of Differentiation 73 (CD73) with high affinity, and inhibit the activity of CD73, and optionally mediate antibody dependent CD73 internalization. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for inhibiting the growth of a tumor cell expressing CD73 using the antibodies of the invention, including methods for treating various cancers.